Targeting local tissues by transdermal application: Understanding drug physicochemical properties that best exploit protein binding and blood flow effects

Drug Development Research

Volumn 46, Issue 3-4, 1999, Pages 309-315

  Cross, Sheree E ^a   Roberts, Michael S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

NSAID; Topical; Vasoconstrictor; Vasodilator

Indexed keywords

DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; NONHUMAN; RAT; TISSUE BLOOD FLOW; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; VASOCONSTRICTION; VASODILATATION;

EID: 0033055305     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199903/04)46:3/4<309::AID-DDR17>3.0.CO;2-H     Document Type: Article

References (41)

1. Baldwin JR, Carrano RA, Imondi AR. 1984. Penetration of trolamine salicylate into the skeletal muscle of the pig. J Pharm Sci 73:1002-1004.
2. Bocci V. 1987. The metabolism of anticancer agents. Pharmacol Ther 34:1-49.
3. Brakkee AJ, Vendrik AJ. 1970. Arterio-venous shunts in peripheral vascular systems. Pflugers Arch 314:170.
4. Chien YW, Siddiqui O, Shi W-M, Lelawongs P, Liu JC. 1989. Direct current iontophoretic transdermal delivery of peptide and protein drugs. J Pharm Sci 78:376-383.
5. Conte L, Ramis J, Mis R, Forn J, Vilaro S, Reina M, Vilageliu J, Basi N. 1992. Percutaneous absorption of 14C-flutrimazole in mini-pigs. Arzneim Forsch 42:847-853.
6. Cross SE, Roberts MS. 1993. Subcutaneous absorption kinetics and local tissue distribution of interferon and other solutes. J Pharm Pharmacol 45:606-609.
7. Cross SE, Wu ZY, Roberts MS. 1994. Effect of perfusion rate on the tissue uptake of solutes after dermal application using the rat isolated perfused hindlimb preparation. J Pharm Pharmacol 46:844-850.
8. Cross SE, Wu ZY, Roberts MS. 1996. The effect of protein binding on the deep tissue penetration and efflux of dermally applied salicylic acid, lidocaine and diazepam in the perfused rat hindlimb. J Pharmacol Exp Ther 277:366-374.
9. Cross SE, Anderson C, Thompson MJ, Roberts MS. 1997. Is there tissue penetration after application of topical salicylate formulations? Lancet 350:636.
10. Cross SE, Anderson C, Roberts MS. 1998a. Topical penetration of commercial salicylate esters and salts using human isolated skin and clinical microdialysis studies. Br J Clin Pharmacol 46:29-35.
11. Cross SE, Megwa SA, Benson HAE, Roberts MS. 1998b. Effect of increases in cutaneous blood flow induced by a topical commercial methylsalicylate formulation on its own absorption and distribution. In: Brain KR, Walters KA, editors. Perspectives of Percutaneous Penetration Vol 6a. Cardiff, UK: STS Publishing Ltd.
12. Dawson M, McGee CM, Vine JH, Nash P, Watson TR, Brooks PM. 1988. The disposition of biphenylacetic acid following topical application. Eur J Clin Pharmacol 33:639-642.
13. Gillette JR. 1973. Overview of drug protein binding. Ann NY Acad Sci 226:6-17.
14. Green BG, Flammer LJ. 1989. Methyl salicylate as a cutaneous stimulus: a psychophysical analysis. Somatosens Mot Res 6:253-274.
15. Hirate J, Kato Y, Horikoshi I, Nagase S, Ueda C. 1989. Further observations on the disposition characteristics of salicylic acid in albuminemic rats. Biopharm Drug Dis 10:299-309.
16. Koch-Weser J, Sellers EM. 1976. Binding of drugs to serum albumin. N Engl J Med 294:311-316.
17. McNeill SC, Potts RO, Francoeur ML. 1992. Local enhanced topical delivery of drugs: Does it really exist? Pharm Res 9:1422-1427.
18. Monterio-Riviere NA, Inman AO, Riviere J, McNeill SC. 1993. Topical penetration of piroxicam is dependent on the distribution of the local cutaneous vasculature. Pharm Res 10:1326-1331.
19. Owen SG, Francis HW, Roberts MS. 1994. Disappearance kinetics of solutes from synovial fluid after infra-articular injection. Br J Clin Pharmacol 38:349-355.
20. Patrick E, Maibach HI, Burkhalter A. 1985. Mechanisms of chemically induced skin irritation. Studies of time course, dose response and components of inflammation in the laboratory mouse. Toxicol Appl Pharmacol 81:476-490.
21. Patrick E, Burkhalter A, Maibach HI. 1987. Recent investigations of mechanisms of chemically induced skin irritation in laboratory mice. J Invest Dermatol 88:24s-31s.
22. Rabinowitz JL, Feldman ES, Weinberger A, Schumacher HR. 1982. Comparative tissue absorption of oral 14C-salicylate in humans and canine knee joints. J Clin Pharmacol 22:42-48.
23. Radermacher J, Jentsch D, Scholl MA, Lustinez T, Frolich JC. 1991. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative disease. Br J Clin Pharmacol 31:537-541.
24. Reiss VW, Schmid K, Botta L, Kobayashi K, Moppert J, Schneider W, Sioufi A, Strusberg A, Tomasi M. 1986. Die perkutane resorption von diclofenac. Arzneim Forsch 36:1092-1096.
25. Riviere JE, Williams PL. 1992. Pharmacokinetic implications of changing blood flow in skin. J Pharm Sci 81:601-602.
26. Riviere JE, Sage B, Williams PL. 1991. Effects of vasoactive drugs on transdermal lidocaine iontophoresis. J Pharm Sci 80:615-620.
27. Riviere JE, Monterio-Riviere NA, Inman AO. 1992. Determination of lidocaine concentrations in skin after transdermal iontophoresis: effects of vasoactive drugs. Pharm Res 9:211-214.
28. Roberts MS. 1991. Structure-permeability considerations in percutaneous absorption. In: Scott RC, Guy RH, Hadgraft J, editors. Predictions of Percutaneous Penetration. London: IBC Technical Services.
29. Roberts MS, Cross SE, Singh P. 1998. Administration of vaso-active agent and therapeutic agent. US Patent No. 5,750,141.
30. RyanTJ. 1983. In: Goldsmith LA, editor. Biochemistry and Physiology of the Skin. Oxford: Oxford Press, p 817-877.
31. Scott GM. 1982. Interferon: pharmacokinetics and toxicity. Phil Trans R Soc Lond B299:91-107.
32. Siddiqui O, Roberts MS, Polack AE. 1989. Percutaneous absorption of steroids: relative contributions of epidermal penetration and dermal clearance. J Pharmacokin Biopharm 17:405-424.
33. Singh P, Roberts MS. 1990. Deep tissue penetration of lignocaine after dermal application. Clin Exp Pharmacol Physiol Suppl 17:71.
34. Singh P, Roberts MS. 1993a. Dermal and underlying tissue pharmaco-kinetics of salicylate after topical application. J Pharmacokin Biopharm 21:337-373.
35. Singh P, Roberts MS. 1993b. Iontophoretic delivery of salicylate and lignocaine to local subcutaneous structures. J Pharm Sci 82:127-131.
36. Singh P, Roberts MS. 1994a. Dermal and underlying tissue pharmacokinetics of lignocaine after topical application. J Pharm Sci 83:774-782.
37. Singh P, Roberts MS. 1994b. Effects of vasoconstriction on dermal pharmacokinetics and local tissue distribution of compounds. J Pharm Sci 83:783-791.
38. Singh P, Roberts MS. 1996. Local deep tissue penetration of compounds after dermal application: structure-tissue penetration relationships. J Pharmacol Exp Ther 279:908-917.
39. Supersaxo A, Hein WR, Steffen H. 1990. Recombinant interferon alpha 2a: delivery to lymphoid tissues by selected modes of application. Pharm Res 7:399-409.
40. Vallner JJ. 1977. Binding of drugs by albumin and plasma protein. J Pharm Sci 66:447-465.
41. Wu ZY, Rivory LP Roberts MS. 1993. Physiological pharmacokinetics of solutes in perfused rat hindlimb: characterisation of the physiology with changing perfusate flow, protein content and temperature using statistical moment analysis. J Pharmacokin Biopharm 21:653-688.